MONTEREY, Calif., Oct. 16 /PRNewswire/ -- PARI's eFlow, an advanced electronic nebulizer, is being used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial initiated this week for the ...
STARNBERG, Germany, June 7, 2016 /PRNewswire/ -- PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow ...
Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological ...
MONTEREY, Calif., April 17 /PRNewswire/ -- An optimized PARI eFlow platform nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase II human clinical trial that has begun enrolling patients.
- ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options - ...
MONTEREY, Calif., Oct. 6 Today, PARI Pharma GmbH willunveil a prototype Closed System using eFlow Technology that uses single doseampoules to control medication used in the nebulizer system. By ...
LANGHORNE, Pa., December 02, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European ...
MONTEREY, Calif., Jan. 3 /PRNewswire/ -- PARI's eFlow was awarded a 2006 GOOD DESIGN Award for medical equipment by The Chicago Athenaeum: Museum of Architecture and Design earlier this month. This is ...
As highlighted in the April issue of Medical Device & Diagnostic Industry magazine, PARI Aerosol Research Institute has been awarded a 2006 Medical Design Excellence Award for eFlow. eFlow is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results